

## Supplementary Material

### A Marked Low-grade Inflammation and a Significant Deterioration in Metabolic Status in First Episode Schizophrenia: a Five-Year Follow-up Study

Madis Parksepp<sup>1,2\*</sup>, Liina Haring<sup>1,3,4</sup>, Kalle Kilk<sup>4</sup>, Egon Taalberg<sup>4</sup>, Raul Kangro<sup>5</sup>, Mihkel Zilmer<sup>4</sup>, Eero Vasar<sup>4</sup>

<sup>1</sup> Institute of Clinical Medicine University of Tartu; Psychiatry Clinic of Tartu University Hospital, Estonia

<sup>2</sup> Psychiatry Clinic of Viljandi Hospital, Estonia; [Madis.Parksepp@vmh.ee](mailto:Madis.Parksepp@vmh.ee) (corresponding author\*)

<sup>3</sup> Psychiatry Clinic of Tartu University Hospital, Estonia; [Liina.Haring@kliinikum.ee](mailto:Liina.Haring@kliinikum.ee)

<sup>4</sup> Institute of Biomedicine and Translational Medicine, Centre of Excellence for Genomics and Translational Medicine, University of Tartu, Estonia; [Kalle.Kilk@ut.ee](mailto:Kalle.Kilk@ut.ee); [Egon.Taalberg@ut.ee](mailto:Egon.Taalberg@ut.ee); [Mihkel.Zilmer@ut.ee](mailto:Mihkel.Zilmer@ut.ee); [Eero.Vasar@ut.ee](mailto:Eero.Vasar@ut.ee)

<sup>5</sup> Institute of Mathematics and Statistics, University of Tartu, Estonia; [Raul.Kangro@ut.ee](mailto:Raul.Kangro@ut.ee)

**Table S1.** Serum mean levels, standard deviations (SD), and range of inflammatory and metabolic protein biomarkers (pg/ml), acylcarnitines, hexoses, body mass index, and waist circumference for control subjects (CSs, n = 58), first-episode psychosis (FEP) patients at baseline (before treatment with antipsychotics, FEP<sub>b</sub>, n = 54), after 0.6-year treatment (FEP<sub>0.6-year</sub>, n = 47), and after 5.1-year treatment (FEP<sub>5.1-year</sub>, n = 38) with antipsychotics. In comparison between reduced and unrestricted models, *p*-values have been multiple tests corrected according to the false discovery rate (FDR) method. The unrestricted regression model is designated as True (i.e. more complex set of predictor variables explained more effectively biomarker level alterations over time) or False (i.e. unrestricted model did not provide more explanatory power than a simple one).

Regression equations for estimating biomarker level or biomarkers ratio alterations.	
Reduced model	$\log(\text{biomarker}) \sim \text{Age} + \text{Gender} + \text{Smoking} + (1   \text{Patient})$
Unrestricted model	$\log(\text{biomarker}) \sim \text{Age} + \text{Gender} + \text{Smoking} + \text{Visit} + \text{Time difference} + (1   \text{Patient})$

Visit = biomarker measurements at three-time points in the patients' group, Time1 = time difference between FEP<sub>b</sub> and FEP<sub>0.6-year</sub>, Time2 = time difference between FEP<sub>0.6-year</sub> and FEP<sub>5.1-year</sub>, (1|Patient) = random effects of patients.

	CSs Mean ± SD Median (range)	FEP <sub>b</sub> Mean ± SD Median (range)	FEP <sub>(0.6-year)</sub> Mean ± SD Median (range)	FEP <sub>(5.1-year)</sub> Mean ± SD Median (range)	Comparison between models	
					Adjusted <i>p</i> -value	True (T) or false (F)
<i>Body mass index (BMI), waist circumference</i>						
BMI	22.6 ± 2.78 22.6 (16.8 – 28.9)	22.8 ± 3.00 22.2 (18.4 – 30.2)	25.3 ± 3.94 24.4 (18.8 – 34.7)	27.8 ± 4.71 27.5 (18.8 – 43.0)	6 × 10 <sup>-12</sup>	T
Waist circumference	77.9 ± 12.6 77.0 (61.0 – 108)	81.0 ± 9.89 79.5 (64.0 – 110)	86.3 ± 11.2 86.0 (68.0 – 114)	94.4 ± 11.2 96.5 (65.0 – 118)	6 × 10 <sup>-11</sup>	T

*Continued.*

	CSs	FEP <sub>b</sub>	FEP <sup>(0.6-year)</sup>	FEP <sup>(5.1-year)</sup>	Comparison between models	
	Mean ± SD Median (range)	Mean ± SD Median (range)	Mean ± SD Median (range)	Mean ± SD Median (range)	Adjusted <i>p</i> -value	True (T) or false (F)
<b>Inflammatory biomarkers</b>						
Interleukin (IL-)2	2.27 ± 1.26 2.50 (0.66 – 6.28)	3.15 ± 0.87 3.06 (1.18 – 6.69)	2.39 ± 1.14 2.10 (1.14 – 7.90)	3.52 ± 1.33 3.60 (0.72 – 8.27)	5 × 10 <sup>-7</sup>	T
IL-4	1.33 ± 0.51 1.26 (0.79 – 3.71)	1.87 ± 0.57 1.79 (1.02 – 3.75)	1.62 ± 0.63 1.41 (0.92 – 4.32)	2.21 ± 0.56 2.24 (0.82 – 3.47)	3 × 10 <sup>-9</sup>	T
IL-6	0.76 ± 0.59 0.59 (0.15 – 2.91)	1.27 ± 1.14 0.87 (0.33 – 5.03)	0.93 ± 0.76 0.72 (0.19 – 4.16)	1.12 ± 0.74 0.90 (0.52 – 4.45)	6 × 10 <sup>-4</sup>	T
IL-8	5.98 ± 2.90 5.61 (1.61 – 13.8)	6.58 ± 4.07 5.59 (1.72 – 17.9)	5.66 ± 3.88 4.30 (1.25 – 17.4)	7.05 ± 3.05 6.59 (2.63 – 14.1)	4 × 10 <sup>-4</sup>	T
IL-10	0.71 ± 0.42 0.59 (0.19 – 2.11)	0.73 ± 0.37 0.73 (0.19 – 1.65)	0.75 ± 0.49 0.65 (0.27 – 2.29)	1.44 ± 0.93 1.13 (0.50 – 4.94)	4 × 10 <sup>-7</sup>	T
IL-1α	0.19 ± 0.13 0.14 (0.060 – 0.61)	0.29 ± 0.23 0.23 (0.060 – 1.33)	0.23 ± 0.19 0.17 (0.07 – 1.26)	0.30 ± 0.11 0.31 (0.060 – 0.58)	2 × 10 <sup>-4</sup>	T
IL-1β	1.63 ± 0.91 1.48 (0.45 – 4.47)	1.41 ± 0.66 1.37 (0.44 – 3.44)	1.37 ± 0.76 1.39 (0.39 – 3.39)	1.60 ± 0.47 1.66 (0.46 – 2.23)	1 × 10 <sup>-1</sup>	F
Interferon gamma (IFN-γ)	0.30 ± 0.090 0.27 (0.19 – 0.55)	0.36 ± 0.14 0.36 (0.19 – 0.92)	0.27 ± 0.12 0.22 (0.17 – 0.69)	0.44 ± 0.21 0.38 (0.16 – 1.14)	3 × 10 <sup>-8</sup>	T
Tumor necrosis factor alpha (TNF-α)	2.22 ± 1.40 1.86 (0.86 – 8.70)	1.98 ± 0.84 1.83 (0.97 – 5.76)	1.91 ± 0.59 1.79 (1.03 – 3.59)	2.39 ± 0.79 2.32 (0.90 – 4.61)	3 × 10 <sup>-3</sup>	T
Monocyte chemoattractant protein-1 (MCP-1)	131 ± 76.7 115 (23.1 – 365)	127 ± 77.4 111 (21.2 – 381)	135 ± 80.2 116 (10.6 – 344)	170 ± 72.1 159 (36.5 – 353)	4 × 10 <sup>-3</sup>	T
Ferritin	43.6 ± 55.2 21.4 (1.22 – 255)	90.0 ± 82.5 62.0 (4.26 – 386)	64.3 ± 75.8 32.5 (5.09 – 342)	92.7 ± 77.8 77.4 (3.35 – 269)	3 × 10 <sup>-3</sup>	T
<b>Metabolic biomarkers</b>						
Resistin	2.53 ± 0.57 2.51 (0.88 – 4.10)	3.15 ± 1.33 2.85 (0.75 – 8.58)	2.78 ± 0.88 2.73 (1.42 – 5.63)	2.18 ± 1.01 1.90 (1.13 – 6.40)	1 × 10 <sup>-4</sup>	T
Insulin	15.6 ± 14.3 9.02 (1.80 – 67.6)	12.9 ± 14.8 7.24 (1.54 – 64.4)	18.3 ± 16.0 12.3 (2.41 – 66.8)	8.28 ± 6.59 7.30 (1.90 – 35.6)	2 × 10 <sup>-2</sup>	F
Leptin	2.07 ± 2.18 1.34 (0.38 – 12.8)	1.40 ± 1.69 0.87 (0.000 – 10.4)	2.59 ± 2.77 1.31 (0.000 – 12.5)	3.29 ± 3.90 1.39 (0.45 – 15.5)	1 × 10 <sup>-4</sup>	T
Plasminogen activator inhibitor-1 (PAI-1)	21.9 ± 9.56 20.5 (6.33 – 49.9)	29.7 ± 13.6 26.5 (2.13 – 61.7)	25.8 ± 14.9 20.9 (4.81 – 73.0)	20.4 ± 12.8 18.1 (0.95 – 63.2)	2 × 10 <sup>-4</sup>	T

*Continued.*

	CSs Mean ± SD Median (range)	FEP <sub>b</sub> Mean ± SD Median (range)	FEP <sub>(0.6-year)</sub> Mean ± SD Median (range)	FEP <sub>(5.1-year)</sub> Mean ± SD Median (range)	Comparison between models	
					Adjusted <i>p</i> -value	True (T) or false (F)
<i>Acylcarnitines</i>						
C0	32.0 ± 7.82 31.8 (16.6 – 51.8)	34.6 ± 7.40 34.4 (18.3 – 52.0)	34.0 ± 9.63 33.4 (15.8 – 58.4)	37.1 ± 10.3 34.2 (18.7 – 67.2)	8 × 10 <sup>-1</sup>	F
C16	0.082 ± 0.021 0.080 (0.035 – 0.13)	0.11 ± 0.032 0.11 (0.046 – 0.20)	0.092 ± 0.029 0.085 (0.041 – 0.20)	0.11 ± 0.040 0.10 (0.057 – 0.22)	1 × 10 <sup>-5</sup>	T
C16-OH	0.009 ± 0.013 0.009 (0.000 – 0.084)	0.017 ± 0.005 0.016 (0.009 – 0.027)	0.019 ± 0.028 0.015 (0.008 – 0.20)	0.053 ± 0.099 0.022 (0.000 – 0.50)	3 × 10 <sup>-2</sup>	F
C16:1	0.026 ± 0.008 0.025 (0.015 – 0.071)	0.036 ± 0.012 0.036 (0.015 – 0.064)	0.028 ± 0.012 0.023 (0.011 – 0.062)	0.039 ± 0.022 0.032 (0.018 – 0.11)	4 × 10 <sup>-5</sup>	T
C16:1-OH	0.007 ± 0.013 0.008 (0.000 – 0.10)	0.014 ± 0.004 0.013 (0.007 – 0.028)	0.014 ± 0.012 0.011 (0.006 – 0.092)	0.034 ± 0.054 0.018 (0.000 – 0.24)	1 × 10 <sup>-2</sup>	F
C16:2	0.014 ± 0.007 0.012 (0.008 – 0.048)	0.015 ± 0.004 0.014 (0.008 – 0.027)	0.013 ± 0.005 0.013 (0.006 – 0.027)	0.026 ± 0.025 0.019 (0.008 – 0.11)	2 × 10 <sup>-5</sup>	T
C16:2-OH	0.016 ± 0.015 0.021 (0.000 – 0.045)	0.027 ± 0.005 0.027 (0.018 – 0.038)	0.029 ± 0.009 0.028 (0.019 – 0.075)	0.027 ± 0.018 0.024 (0.000 – 0.085)	2 × 10 <sup>-3</sup>	T
C18:0	0.039 ± 0.009 0.038 (0.022 – 0.073)	0.046 ± 0.013 0.046 (0.025 – 0.085)	0.042 ± 0.013 0.040 (0.022 – 0.074)	0.052 ± 0.021 0.043 (0.026 – 0.12)	3 × 10 <sup>-3</sup>	T
C18:1	0.096 ± 0.030 0.092 (0.058 – 0.18)	0.14 ± 0.046 0.14 (0.049 – 0.27)	0.096 ± 0.041 0.086 (0.039 – 0.27)	0.14 ± 0.048 0.13 (0.072 – 0.27)	8 × 10 <sup>-8</sup>	T
C18:1-OH	0.017 ± 0.018 0.015 (0.000 – 0.075)	0.028 ± 0.012 0.024 (0.013 – 0.053)	0.027 ± 0.016 0.017 (0.011 – 0.075)	0.031 ± 0.024 0.020 (0.000 – 0.10)	4 × 10 <sup>-3</sup>	T
C18:2	0.031 ± 0.009 0.029 (0.013 – 0.055)	0.042 ± 0.014 0.039 (0.020–0.081)	0.033 ± 0.015 0.030 (0.015 – 0.094)	0.047 ± 0.015 0.048 (0.025 – 0.093)	6 × 10 <sup>-7</sup>	T
C2	4.96 ± 1.68 4.90 (1.78 – 11.3)	4.65 ± 3.47 3.38 (0.51 – 14.0)	4.21 ± 1.70 3.95 (0.98 – 7.90)	6.97 ± 2.67 6.55 (3.16 – 13.2)	1 × 10 <sup>-6</sup>	T
C3	0.36 ± 0.11 0.36 (0.13 – 0.61)	0.25 ± 0.077 0.23 (0.14 – 0.49)	0.33 ± 0.13 0.30 (0.14 – 0.65)	0.54 ± 0.17 0.504 (0.28 – 1.00)	1 × 10 <sup>-18</sup>	T
C3-DC(C4-OH)	0.036 ± 0.023 0.043 (0.000 – 0.092)	0.062 ± 0.048 0.053 (0.025 – 0.32)	0.049 ± 0.017 0.045 (0.029 – 0.13)	0.050 ± 0.028 0.042 (0.000 – 0.12)	3 × 10 <sup>-3</sup>	T
C5-OH(C3-DC-M)	0.035 ± 0.032 0.049 (0.000 – 0.091)	0.060 ± 0.015 0.057 (0.036 – 0.11)	0.061 ± 0.015 0.059 (0.035 – 0.12)	0.062 ± 0.029 0.055 (0.000 – 0.15)	3 × 10 <sup>-5</sup>	T

*Continued.*

	CSs	FEP <sub>b</sub>	FEP <sub>(0.6-year)</sub>	FEP <sub>(5.1-year)</sub>	Comparison between models	
	Mean ± SD Median (range)	Mean ± SD Median (range)	Mean ± SD Median (range)	Mean ± SD Median (range)	Adjusted <i>p</i> -value	True (T) or false (F)
<b>Acylcarnitines</b>						
C3-OH	0.028 ± 0.037 0.035 (0.000 – 0.25)	0.038 ± 0.010 0.040 (0.018 – 0.066)	0.043 ± 0.018 0.039 (0.023 – 0.14)	0.062 ± 0.060 0.044 (0.000 – 0.31)	2 × 10 <sup>-2</sup>	F
C3:1	0.018 ± 0.017 0.026 (0.000 – 0.069)	0.030 ± 0.007 0.030 (0.018 – 0.048)	0.036 ± 0.035 0.031 (0.019 – 0.26)	0.042 ± 0.029 0.035 (0.000 – 0.12)	6 × 10 <sup>-3</sup>	F
C4	0.22 ± 0.069 0.21 (0.12 – 0.42)	0.15 ± 0.043 0.15 (0.071 – 0.32)	0.17 ± 0.052 0.17 (0.077 – 0.31)	0.32 ± 0.11 0.31 (0.13 – 0.56)	1 × 10 <sup>-15</sup>	T
C4:1	0.026 ± 0.025 0.036 (0.000 – 0.089)	0.046 ± 0.009 0.046 (0.027 – 0.061)	0.051 ± 0.033 0.045 (0.030 – 0.26)	0.064 ± 0.038 0.060 (0.000 – 0.16)	2 × 10 <sup>-5</sup>	T
C5	0.17 ± 0.050 0.16 (0.000 – 0.32)	0.14 ± 0.042 0.14 (0.065 – 0.31)	0.17 ± 0.069 0.16 (0.075 – 0.39)	0.18 ± 0.067 0.18 (0.073 – 0.34)	4 × 10 <sup>-4</sup>	T
C5-M-DC	0.023 ± 0.021 0.031 (0.000 – 0.074)	0.034 ± 0.011 0.037 (0.014 – 0.059)	0.036 ± 0.013 0.036 (0.010 – 0.089)	0.030 ± 0.022 0.023 (0.000 – 0.10)	2 × 10 <sup>-2</sup>	F
C5:1	0.044 ± 0.040 0.056 (0.000 – 0.12)	0.076 ± 0.017 0.075 (0.040 – 0.14)	0.074 ± 0.021 0.071 (0.043 – 0.17)	0.091 ± 0.057 0.078 (0.000 – 0.28)	5 × 10 <sup>-4</sup>	T
C5:1-DC	0.015 ± 0.014 0.020 (0.000 – 0.053)	0.023 ± 0.006 0.025 (0.010 – 0.032)	0.024 ± 0.008 0.023 (0.010 – 0.053)	0.024 ± 0.017 0.019 (0.000 – 0.083)	1 × 10 <sup>-2</sup>	F
<b>Hexoses, ratios of acylcarnitines</b>						
Hexoses	4144 ± 823 4094 (2780 – 6663)	4258 ± 750 4075 (2802 – 5918)	4287 ± 867 4264 (2760 – 7189)	4887 ± 1104 4711 (3086 – 7271)	1 × 10 <sup>-3</sup>	T
(C16+C18)/C0	0.0040 ± 0.0013 0.0036 (0.0023 – 0.0092)	0.0049 ± 0.0016 0.0046 (0.0019 – 0.010)	0.0041 ± 0.0011 0.0037 (0.0025 – 0.0069)	0.0046 ± 0.0020 0.0041 (0.0020 – 0.010)	5 × 10 <sup>-3</sup>	T
(C16+C18:1)/C2	0.043 ± 0.015 0.038 (0.023 – 0.092)	0.085 ± 0.082 0.063 (0.022 – 0.50)	0.054 ± 0.047 0.042 (0.018 – 0.28)	0.037 ± 0.009 0.034 (0.019 – 0.056)	5 × 10 <sup>-10</sup>	T
(C2+C3+C4+C5)/C0	0.19 ± 0.091 0.18 (0.066 – 0.73)	0.16 ± 0.12 0.12 (0.024 – 0.55)	0.16 ± 0.086 0.16 (0.033 – 0.61)	0.22 ± 0.084 0.20 (0.11 – 0.44)	2 × 10 <sup>-5</sup>	T

**Table S2.** Estimated effects of the complex set of predictor variables on serum concentrations of inflammatory and metabolic protein biomarkers, acylcarnitines, hexoses, body mass index and waist circumference between control subjects (CSs, n = 58), first-episode psychosis patients at baseline (before treatment with antipsychotics, FEP<sub>b</sub>, n = 54), after 0.6-year treatment (FEP<sub>0.6-year</sub>, n = 47), and after 5.1-year treatment (FEP<sub>5.1-year</sub>, n = 38) with antipsychotics: results from linear mixed-effects model.

	Intercept	Age	Gender	Smoking status	Disease and Treatment Effect			Time-Diff1	Time-Diff2
					FEP patients before treatment	FEP patients after 0.6-year treatment	FEP patients after 5.1-year treatment		
	Effects of Independent Variables on the Dependent Variable ( <i>F</i> -Value, <i>p</i> -Value)								
	<i>t</i> -Value, <i>p</i> -Value								
<b>Body mass index (BMI), waist circumference</b>									
BMI	$F_{(1,110)} = 1798$ , $p < 1 \times 10^{-4}$	$F_{(1,77)} = 2.83$ , $p = 0.10$	$F_{(1,110)} = 0.41$ , $p = 0.52$	$F_{(2,77)} = 0.39$ , $p = 0.67$	$F_{(3,77)} = 26.88$ , $p < 1 \times 10^{-4}$			$F_{(1,77)} = 1.29$ , $p = 0.26$	$F_{(1,77)} = 3.90$ , $p = 0.05$
					$t_{(77)} = -0.13$ , $p = 0.90$	$t_{(77)} = 3.59$ , $p = 6 \times 10^{-4}$	$t_{(77)} = 4.63$ , $p < 1 \times 10^{-4}$		
Waist circumference	$F_{(1,110)} = 5466$ , $p < 1 \times 10^{-4}$	$F_{(1,77)} = 1.00$ , $p = 0.32$	$F_{(1,110)} = 24.18$ , $p < 1 \times 10^{-4}$	$F_{(2,77)} = 0.66$ , $p = 0.52$	$F_{(3,77)} = 24.27$ , $p < 1 \times 10^{-4}$			$F_{(1,77)} = 0.24$ , $p = 0.62$	$F_{(1,77)} = 0.19$ , $p = 0.67$
					$t_{(77)} = 0.91$ , $p = 0.36$	$t_{(77)} = 4.00$ , $p = 1 \times 10^{-4}$	$t_{(77)} = 5.50$ , $p < 1 \times 10^{-4}$		
<b>Inflammatory biomarkers</b>									
Interleukin (IL)-2	$F_{(1,109)} = 9.84$ , $p = 2 \times 10^{-3}$	$F_{(1,73)} = 0.01$ , $p = 0.92$	$F_{(1,109)} = 0.95$ , $p = 0.33$	$F_{(2,73)} = 0.70$ , $p = 0.50$	$F_{(3,73)} = 15.85$ , $p < 1 \times 10^{-4}$			$F_{(1,73)} = 0.28$ , $p = 0.60$	$F_{(1,73)} = 0.39$ , $p = 0.53$
					$t_{(73)} = 4.92$ , $p < 1 \times 10^{-4}$	$t_{(73)} = 1.61$ , $p = 0.11$	$t_{(73)} = 4.31$ , $p = 1 \times 10^{-4}$		
IL-4	$F_{(1,109)} = 0.0007$ , $p = 0.98$	$F_{(1,72)} = 0.12$ , $p = 0.73$	$F_{(1,109)} = 3.68$ , $p = 0.06$	$F_{(2,72)} = 0.53$ , $p = 0.59$	$F_{(3,72)} = 19.80$ , $p < 1 \times 10^{-4}$			$F_{(1,72)} = 0.004$ , $p = 0.95$	$F_{(1,72)} = 0.34$ , $p = 0.56$
					$t_{(72)} = 5.95$ , $p < 1 \times 10^{-4}$	$t_{(72)} = 3.43$ , $p = 1 \times 10^{-3}$	$t_{(72)} = 6.52$ , $p < 1 \times 10^{-4}$		
IL-6	$F_{(1,109)} = 2.51$ , $p = 0.12$	$F_{(1,72)} = 0.33$ , $p = 0.56$	$F_{(1,109)} = 0.19$ , $p = 0.67$	$F_{(2,72)} = 3.83$ , $p = 0.03$	$F_{(3,72)} = 7.53$ , $p = 2 \times 10^{-4}$			$F_{(1,72)} = 0.15$ , $p = 0.70$	$F_{(1,72)} = 0.0001$ , $p = 0.99$
					$t_{(72)} = 4.22$ , $p = 1 \times 10^{-4}$	$t_{(72)} = 2.19$ , $p = 0.03$	$t_{(72)} = 3.80$ , $p = 3 \times 10^{-4}$		
IL-8	$F_{(1,109)} = 60.06$ , $p < 1 \times 10^{-4}$	$F_{(1,72)} = 3.83$ , $p = 0.05$	$F_{(1,108)} = 0.93$ , $p = 0.34$	$F_{(2,72)} = 0.68$ , $p = 0.51$	$F_{(3,72)} = 2.70$ , $p = 0.05$			$F_{(1,72)} = 13.00$ , $p = 6 \times 10^{-4}$	$F_{(1,72)} = 2.88$ , $p = 0.09$
					$t_{(72)} = 0.65$ , $p = 0.52$	$t_{(72)} = -0.51$ , $p = 0.62$	$t_{(72)} = 1.59$ , $p = 0.11$		

*Continued.*

	Intercept	Age	Gender	Smoking status	Disease and Treatment Effect			Time-Diff1	Time-Diff2
					FEP patients before treatment	FEP patients after 0.6-year treatment	FEP patients after 5.1-year treatment		
	Effects of Independent Variables on the Dependent Variable ( <i>F</i> -Value, <i>p</i> -Value)								
	<i>t</i> -Value, <i>p</i> -Value								
<i>Inflammatory biomarkers</i>									
IL-10	$F_{(1,109)} = 0.57, p = 0.45$	$F_{(1,73)} = 0.72, p = 0.40$	$F_{(1,109)} = 0.44, p = 0.51$	$F_{(2,73)} = 2.27, p = 0.11$	$F_{(3,73)} = 14.42, p < 1 \times 10^{-4}$			$F_{(1,73)} = 0.64, p = 0.43$	$F_{(1,73)} = 0.002, p = 0.96$
					$t_{(73)} = 0.80, p = 0.43$	$t_{(73)} = 0.72, p = 0.48$	$t_{(73)} = 5.82, p < 1 \times 10^{-4}$		
IL-1A	$F_{(1,109)} = 41.84, p < 1 \times 10^{-4}$	$F_{(1,73)} = 0.01, p = 0.92$	$F_{(1,109)} = 0.06, p = 0.80$	$F_{(2,73)} = 1.31, p = 0.28$	$F_{(3,73)} = 9.21, p < 1 \times 10^{-4}$			$F_{(1,73)} = 0.008, p = 0.93$	$F_{(1,73)} = 0.33, p = 0.57$
					$t_{(73)} = 3.44, p = 1 \times 10^{-3}$	$t_{(73)} = 2.00, p = 0.05$	$t_{(73)} = 4.32, p < 1 \times 10^{-4}$		
IL-1B	$F_{(1,108)} = 8.21, p = 5 \times 10^{-3}$	$F_{(1,72)} = 6.69, p = 0.01$	$F_{(1,108)} = 0.28, p = 0.59$	$F_{(2,72)} = 0.94, p = 0.40$	$F_{(3,72)} = 2.04, p = 0.12$			$F_{(1,72)} = 0.03, p = 0.86$	$F_{(1,72)} = 1.14, p = 0.29$
					$t_{(72)} = -0.72, p = 0.47$	$t_{(72)} = -1.34, p = 0.19$	$t_{(72)} = 0.89, p = 0.37$		
Interferon gamma (IFN-γ)	$F_{(1,108)} = 53.20, p < 1 \times 10^{-4}$	$F_{(1,70)} = 0.19, p = 0.66$	$F_{(1,108)} = 0.49, p = 0.48$	$F_{(2,70)} = 2.26, p = 0.11$	$F_{(3,70)} = 14.34, p < 1 \times 10^{-4}$			$F_{(1,70)} = 0.47, p = 0.49$	$F_{(1,70)} = 3.87, p = 0.05$
					$t_{(70)} = 2.64, p = 0.01$	$t_{(70)} = -1.52, p = 0.13$	$t_{(70)} = 3.74, p = 4 \times 10^{-4}$		
Tumor necrosis factor-alpha (TNF-α)	$F_{(1,109)} = 24.72, p < 1 \times 10^{-4}$	$F_{(1,72)} = 1.65, p = 0.20$	$F_{(1,109)} = 3.19, p = 0.08$	$F_{(2,72)} = 1.77, p = 0.18$	$F_{(3,72)} = 3.73, p = 0.01$			$F_{(1,72)} = 1.45, p = 0.23$	$F_{(1,72)} = 4.62, p = 0.03$
					$t_{(72)} = -0.62, p = 0.54$	$t_{(72)} = -0.88, p = 0.38$	$t_{(72)} = 1.41, p = 0.16$		
Monocyte chemoattractant protein-1 (MCP-1)	$F_{(1,109)} = 318.9, p < 1 \times 10^{-4}$	$F_{(1,73)} = 5.95, p = 0.02$	$F_{(1,109)} = 1.44, p = 0.23$	$F_{(2,73)} = 1.48, p = 0.23$	$F_{(3,73)} = 4.03, p = 0.01$			$F_{(1,73)} = 0.0001, p = 0.99$	$F_{(1,73)} = 4.54, p = 0.04$
					$t_{(73)} = -0.02, p = 0.98$	$t_{(73)} = 0.42, p = 0.67$	$t_{(73)} = 2.48, p = 0.02$		
Ferritin	$F_{(1,109)} = 86.73, p < 1 \times 10^{-4}$	$F_{(1,74)} = 4.75, p = 0.03$	$F_{(1,109)} = 76.03, p < 1 \times 10^{-4}$	$F_{(2,74)} = 0.20, p = 0.82$	$F_{(3,74)} = 6.07, p = 9 \times 10^{-4}$			$F_{(1,74)} = 0.92, p = 0.34$	$F_{(1,74)} = 0.39, p = 0.54$
					$t_{(74)} = 3.52, p = 7 \times 10^{-4}$	$t_{(74)} = 1.29, p = 0.20$	$t_{(74)} = 1.99, p = 0.05$		

Continued.

	Intercept	Age	Gender	Smoking status	Disease and Treatment Effect			Time-Diff1	Time-Diff2
					FEP patients before treatment	FEP patients after 0.6-year treatment	FEP patients after 5.1-year treatment		
	Effects of Independent Variables on the Dependent Variable ( <i>F</i> -Value, <i>p</i> -Value)								
	<i>t</i> -Value, <i>p</i> -Value								
<i>Metabolic biomarkers</i>									
Resistin	$F_{(1,109)} = 32.53$ , $p < 1 \times 10^{-4}$	$F_{(1,74)} = 0.17$ , $p = 0.68$	$F_{(1,109)} = 0.04$ , $p = 0.84$	$F_{(2,74)} = 0.25$ , $p = 0.78$	$F_{(3,74)} = 8.96$ , $p = 1 \times 10^{-4}$			$F_{(1,74)} = 0.10$ , $p = 0.76$	$F_{(1,74)} = 0.54$ , $p = 0.46$
					$t_{(74)} = 2.68$ , $p = 9 \times 10^{-3}$	$t_{(74)} = 0.77$ , $p = 0.44$	$t_{(74)} = -2.40$ , $p = 0.02$		
Insulin	$F_{(1,108)} = 60.79$ , $p < 1 \times 10^{-4}$	$F_{(1,74)} = 1.03$ , $p = 0.31$	$F_{(1,108)} = 0.18$ , $p = 0.67$	$F_{(2,74)} = 0.98$ , $p = 0.38$	$F_{(3,74)} = 4.12$ , $p = 9 \times 10^{-3}$			$F_{(1,74)} = 0.52$ , $p = 0.47$	$F_{(1,74)} = 1.29$ , $p = 0.26$
					$t_{(74)} = -1.35$ , $p = 0.18$	$t_{(74)} = 1.17$ , $p = 0.25$	$t_{(74)} = -2.15$ , $p = 0.03$		
Leptin	$F_{(1,108)} = 0.47$ , $p = 0.49$	$F_{(1,71)} = 0.94$ , $p = 0.33$	$F_{(1,108)} = 34.62$ , $p < 1 \times 10^{-4}$	$F_{(2,71)} = 0.67$ , $p = 0.51$	$F_{(3,71)} = 9.11$ , $p < 1 \times 10^{-4}$			$F_{(1,71)} = 0.27$ , $p = 0.60$	$F_{(1,71)} = 0.93$ , $p = 0.34$
					$t_{(71)} = -0.33$ , $p = 0.74$	$t_{(71)} = 2.29$ , $p = 0.02$	$t_{(74)} = 3.43$ , $p = 1 \times 10^{-3}$		
Plasminogen activator inhibitor-1 (PAI-1)	$F_{(1,109)} = 68.21$ , $p < 1 \times 10^{-4}$	$F_{(1,73)} = 2.18$ , $p = 0.14$	$F_{(1,109)} = 0.14$ , $p = 0.71$	$F_{(2,73)} = 6.10$ , $p = 4 \times 10^{-3}$	$F_{(3,74)} = 8.62$ , $p = 1 \times 10^{-4}$			$F_{(1,73)} = 0.79$ , $p = 0.38$	$F_{(1,73)} = 1.05$ , $p = 0.31$
					$t_{(73)} = 2.03$ , $p = 0.05$	$t_{(73)} = 0.39$ , $p = 0.70$	$t_{(73)} = -2.86$ , $p = 6 \times 10^{-3}$		
<i>Acylcarnitines</i>									
C0	$F_{(1,109)} = 1008$ , $p < 1 \times 10^{-4}$	$F_{(1,74)} = 0.71$ , $p = 0.40$	$F_{(1,109)} = 17.05$ , $p = 1 \times 10^{-4}$	$F_{(2,74)} = 0.02$ , $p = 0.98$	$F_{(3,74)} = 0.66$ , $p = 0.58$			$F_{(1,74)} = 0.03$ , $p = 0.87$	$F_{(1,74)} = 0.09$ , $p = 0.76$
					$t_{(74)} = 0.96$ , $p = 0.34$	$t_{(74)} = 0.42$ , $p = 0.67$	$t_{(74)} = 1.26$ , $p = 0.21$		
C16	$F_{(1,109)} = 381.8$ , $p < 1 \times 10^{-4}$	$F_{(1,73)} = 2.09$ , $p = 0.15$	$F_{(1,109)} = 3.71$ , $p = 0.06$	$F_{(2,73)} = 2.75$ , $p = 0.07$	$F_{(3,73)} = 10.42$ , $p < 1 \times 10^{-4}$			$F_{(1,73)} = 1.55$ , $p = 0.22$	$F_{(1,73)} = 1.32$ , $p = 0.25$
					$t_{(73)} = 5.25$ , $p < 1 \times 10^{-4}$	$t_{(73)} = 1.36$ , $p = 0.18$	$t_{(73)} = 3.02$ , $p = 3 \times 10^{-3}$		
C16-OH	$F_{(1,109)} = 0.04$ , $p = 0.85$	$F_{(1,74)} = 0.05$ , $p = 0.82$	$F_{(1,109)} = 0.02$ , $p = 0.89$	$F_{(2,74)} = 0.52$ , $p = 0.59$	$F_{(3,74)} = 4.00$ , $p = 0.01$			$F_{(1,74)} = 0.04$ , $p = 0.84$	$F_{(1,74)} = 0.40$ , $p = 0.53$
					$t_{(74)} = 0.66$ , $p = 0.51$	$t_{(74)} = 0.92$ , $p = 0.36$	$t_{(74)} = 3.26$ , $p = 2 \times 10^{-3}$		
C16:1	$F_{(1,91)} = 557.2$ , $p < 1 \times 10^{-4}$	$F_{(1,71)} = 0.92$ , $p = 0.34$	$F_{(1,91)} = 0.67$ , $p = 0.41$	$F_{(2,71)} = 1.14$ , $p = 0.33$	$F_{(3,71)} = 8.44$ , $p = 1 \times 10^{-4}$			$F_{(1,71)} = 2.30$ , $p = 0.13$	$F_{(1,71)} = 1.23$ , $p = 0.27$
					$t_{(71)} = 3.96$ , $p = 2 \times 10^{-4}$	$t_{(71)} = 0.50$ , $p = 0.62$	$t_{(71)} = 3.40$ , $p = 1 \times 10^{-3}$		

Continued.

	Intercept	Age	Gender	Smoking status	Disease and Treatment Effect			Time-Diff1	Time-Diff2
					FEP patients before treatment	FEP patients after 0.6-year treatment	FEP patients after 5.1-year treatment		
	Effects of Independent Variables on the Dependent Variable ( <i>F</i> -Value, <i>p</i> -Value)								
	<i>t</i> -Value, <i>p</i> -Value								
<b>Acylcarnitines</b>									
C16:1-OH	$F_{(1,109)} = 0.02$ , $p = 0.88$	$F_{(1,74)} = 0.36$ , $p = 0.58$	$F_{(1,109)} = 0.08$ , $p = 0.77$	$F_{(2,74)} = 0.20$ , $p = 0.82$	$F_{(3,74)} = 4.67, p = 5 \times 10^{-3}$			$F_{(1,74)} = 0.02$ , $p = 0.89$	$F_{(1,74)} = 0.32$ , $p = 0.57$
					$t_{(74)} = 1.13$ , $p = 0.26$	$t_{(74)} = 1.07$ , $p = 0.29$	$t_{(74)} = 3.56$ , $p = 6 \times 10^{-4}$		
C16:2	$F_{(1,84)} = 535.1$ , $p < 1 \times 10^{-4}$	$F_{(1,71)} = 0.20$ , $p = 0.66$	$F_{(1,84)} = 0.13$ , $p = 0.71$	$F_{(2,71)} = 0.47$ , $p = 0.63$	$F_{(3,71)} = 9.31, p < 1 \times 10^{-4}$			$F_{(1,71)} = 1.78$ , $p = 0.19$	$F_{(1,71)} = 0.69$ , $p = 0.41$
					$t_{(71)} = 1.20$ , $p = 0.24$	$t_{(71)} = -0.30$ , $p = 0.76$	$t_{(71)} = 4.26$ , $p = 1 \times 10^{-4}$		
C16:2-OH	$F_{(1,109)} = 4.90$ , $p = 0.03$	$F_{(1,74)} = 1.76$ , $p = 0.19$	$F_{(1,109)} = 0.46$ , $p = 0.50$	$F_{(2,74)} = 0.70$ , $p = 0.50$	$F_{(3,74)} = 6.77, p = 4 \times 10^{-4}$			$F_{(1,74)} = 0.03$ , $p = 0.87$	$F_{(1,74)} = 0.40$ , $p = 0.53$
					$t_{(74)} = 3.70$ , $p = 4 \times 10^{-4}$	$t_{(74)} = 4.35$ , $p < 1 \times 10^{-4}$	$t_{(74)} = 2.97$ , $p = 4 \times 10^{-3}$		
C18	$F_{(1,103)} = 603.2$ , $p < 1 \times 10^{-4}$	$F_{(1,74)} = 0.78$ , $p = 0.38$	$F_{(1,103)} = 0.45$ , $p = 0.50$	$F_{(2,74)} = 0.05$ , $p = 0.95$	$F_{(3,74)} = 5.12, p = 3 \times 10^{-3}$			$F_{(1,74)} = 0.57$ , $p = 0.45$	$F_{(1,74)} = 2.50$ , $p = 0.12$
					$t_{(74)} = 2.63$ , $p = 0.01$	$t_{(74)} = 0.63$ , $p = 0.53$	$t_{(74)} = 3.04$ , $p = 3 \times 10^{-3}$		
C18:1	$F_{(1,89)} = 245.7$ , $p < 1 \times 10^{-4}$	$F_{(1,72)} = 0.66$ , $p = 0.42$	$F_{(1,89)} = 0.05$ , $p = 0.82$	$F_{(2,72)} = 1.20$ , $p = 0.31$	$F_{(3,72)} = 16.02, p < 1 \times 10^{-4}$			$F_{(1,72)} = 2.53$ , $p = 0.12$	$F_{(1,72)} = 0.0005$ , $p = 0.98$
					$t_{(72)} = 4.72$ , $p < 1 \times 10^{-4}$	$t_{(72)} = -0.02$ , $p = 0.98$	$t_{(72)} = 4.01$ , $p = 1 \times 10^{-4}$		
C18:1-OH	$F_{(1,109)} = 8.28$ , $p = 5 \times 10^{-3}$	$F_{(1,74)} = 0.11$ , $p = 0.74$	$F_{(1,109)} = 1.55$ , $p = 0.22$	$F_{(2,74)} = 2.49$ , $p = 0.09$	$F_{(3,74)} = 5.49, p = 2 \times 10^{-3}$			$F_{(1,74)} = 1.55$ , $p = 0.22$	$F_{(1,74)} = 0.12$ , $p = 0.73$
					$t_{(74)} = 3.27$ , $p = 2 \times 10^{-3}$	$t_{(74)} = 2.90$ , $p = 5 \times 10^{-3}$	$t_{(74)} = 3.48$ , $p = 9 \times 10^{-4}$		
C18:2	$F_{(1,99)} = 517.0$ , $p < 1 \times 10^{-4}$	$F_{(1,72)} = 1.36$ , $p = 0.25$	$F_{(1,99)} = 2.09$ , $p = 0.15$	$F_{(2,72)} = 0.10$ , $p = 0.91$	$F_{(3,72)} = 13.85, p < 1 \times 10^{-4}$			$F_{(1,72)} = 1.62$ , $p = 0.21$	$F_{(1,72)} = 0.41$ , $p = 0.52$
					$t_{(72)} = 3.87$ , $p = 2 \times 10^{-4}$	$t_{(72)} = 0.16$ , $p = 0.87$	$t_{(72)} = 4.33$ , $p < 1 \times 10^{-4}$		

Continued.



	Intercept	Age	Gender	Smoking status	Disease and Treatment Effect			Time-Diff1	Time-Diff2		
					FEP patients before treatment	FEP patients after 0.6-year treatment	FEP patients after 5.1-year treatment				
					Effects of Independent Variables on the Dependent Variable ( <i>F</i> -Value, <i>p</i> -Value)						
					<i>t</i> -Value, <i>p</i> -Value						
Acylcarnitines											
C2	$F_{(1,109)} = 57.05$ , $p < 1 \times 10^{-4}$	$F_{(1,73)} = 2.77$ , $p = 0.10$	$F_{(1,109)} = 3.38$ , $p = 0.07$	$F_{(2,73)} = 4.70$ , $p = 0.01$	$F_{(3,73)} = 13.25, p < 1 \times 10^{-4}$			$F_{(1,73)} = 0.004$ , $p = 0.95$	$F_{(1,73)} = 0.41$ , $p = 0.52$		
					$t_{(73)} = -2.02$ , $p = 0.05$	$t_{(73)} = -1.36$ , $p = 0.18$	$t_{(73)} = 4.24$ , $p = 1 \times 10^{-4}$				
C3	$F_{(1,109)} = 17.30$ , $p = 1 \times 10^{-4}$	$F_{(1,73)} = 1.86$ , $p = 0.18$	$F_{(1,109)} = 10.15$ , $p = 2 \times 10^{-3}$	$F_{(2,73)} = 0.60$ , $p = 0.55$	$F_{(3,73)} = 43.78, p < 1 \times 10^{-4}$			$F_{(1,73)} = 0.39$ , $p = 0.53$	$F_{(1,73)} = 4.57$ , $p = 0.04$		
					$t_{(73)} = -5.79$ , $p < 1 \times 10^{-4}$	$t_{(73)} = -1.80$ , $p = 0.08$	$t_{(73)} = 5.27$ , $p < 1 \times 10^{-4}$				
C3-DC(C4-OH)	$F_{(1,109)} = 0.60$ , $p = 0.44$	$F_{(1,74)} = 2.98$ , $p = 0.09$	$F_{(1,109)} = 1.49$ , $p = 0.22$	$F_{(2,74)} = 1.04$ , $p = 0.36$	$F_{(3,74)} = 6.17, p = 8 \times 10^{-4}$			$F_{(1,74)} = 0.22$ , $p = 0.64$	$F_{(1,74)} = 0.005$ , $p = 0.94$		
					$t_{(74)} = 4.28$ , $p = 1 \times 10^{-4}$	$t_{(74)} = 2.16$ , $p = 0.03$	$t_{(74)} = 1.60$ , $p = 0.11$				
C5-OH(C3-DC-M)	$F_{(1,109)} = 13.18$ , $p = 4 \times 10^{-4}$	$F_{(1,74)} = 0.04$ , $p = 0.83$	$F_{(1,109)} = 1.21$ , $p = 0.27$	$F_{(2,74)} = 2.19$ , $p = 0.12$	$F_{(3,74)} = 11.15, p < 1 \times 10^{-4}$			$F_{(1,74)} = 0.04$ , $p = 0.84$	$F_{(1,74)} = 0.0002$ , $p = 0.99$		
					$t_{(74)} = 4.94$ , $p < 1 \times 10^{-4}$	$t_{(74)} = 5.06$ , $p < 1 \times 10^{-4}$	$t_{(74)} = 4.69$ , $p < 1 \times 10^{-4}$				
C3-OH	$F_{(1,109)} = 1.17$ , $p = 0.28$	$F_{(1,74)} = 0.09$ , $p = 0.77$	$F_{(1,109)} = 0.21$ , $p = 0.65$	$F_{(2,74)} = 0.14$ , $p = 0.87$	$F_{(3,74)} = 4.77, p = 4 \times 10^{-3}$			$F_{(1,74)} = 0.10$ , $p = 0.75$	$F_{(1,74)} = 0.06$ , $p = 0.81$		
					$t_{(74)} = 1.49$ , $p = 0.14$	$t_{(74)} = 1.93$ , $p = 0.06$	$t_{(74)} = 3.70$ , $p = 4 \times 10^{-4}$				
C3:1	$F_{(1,109)} = 0.45$ , $p = 0.50$	$F_{(1,74)} = 3.28$ , $p = 0.07$	$F_{(1,109)} = 0.16$ , $p = 0.69$	$F_{(2,74)} = 0.01$ , $p = 0.99$	$F_{(3,74)} = 5.44, p = 2 \times 10^{-3}$			$F_{(1,74)} = 0.48$ , $p = 0.49$	$F_{(1,74)} = 0.007$ , $p = 0.93$		
					$t_{(74)} = 2.33$ , $p = 0.02$	$t_{(74)} = 3.38$ , $p = 1 \times 10^{-3}$	$t_{(74)} = 3.49$ , $p = 1 \times 10^{-3}$				
C4	$F_{(1,109)} = 99.47$ , $p < 1 \times 10^{-4}$	$F_{(1,73)} = 0.12$ , $p = 0.72$	$F_{(1,109)} = 0.58$ , $p = 0.45$	$F_{(2,73)} = 0.12$ , $p = 0.88$	$F_{(3,73)} = 35.34, p < 1 \times 10^{-4}$			$F_{(1,73)} = 0.44$ , $p = 0.51$	$F_{(1,73)} = 1.25$ , $p = 0.27$		
					$t_{(73)} = -5.64$ , $p < 1 \times 10^{-4}$	$t_{(73)} = -4.43$ , $p < 1 \times 10^{-4}$	$t_{(73)} = 4.72$ , $p < 1 \times 10^{-4}$				
C4:1	$F_{(1,109)} = 2.17$ , $p = 0.14$	$F_{(1,74)} = 2.04$ , $p = 0.16$	$F_{(1,109)} = 0.24$ , $p = 0.62$	$F_{(2,74)} = 0.01$ , $p = 0.99$	$F_{(3,74)} = 10.53, p < 1 \times 10^{-4}$			$F_{(1,74)} = 0.50$ , $p = 0.48$	$F_{(1,74)} = 0.18$ , $p = 0.67$		
					$t_{(74)} = 3.40$ , $p = 1 \times 10^{-3}$	$t_{(74)} = 4.13$ , $p = 1 \times 10^{-4}$	$t_{(74)} = 5.23$ , $p < 1 \times 10^{-4}$				

Continued.

	Intercept	Age	Gender	Smoking status	Disease and Treatment Effect			Time-Diff1	Time-Diff2
					FEP patients before treatment	FEP patients after 0.6-year treatment	FEP patients after 5.1-year treatment		
	Effects of Independent Variables on the Dependent Variable ( <i>F</i> -Value, <i>p</i> -Value)								
	<i>t</i> -Value, <i>p</i> -Value								
Acylcarnitines									
C5	$F_{(1,109)} = 91.05$ , $p < 1 \times 10^{-4}$	$F_{(1,74)} = 1.76$ , $p = 0.19$	$F_{(1,109)} = 12.03$ , $p = 8 \times 10^{-4}$	$F_{(2,74)} = 0.86$ , $p = 0.43$	$F_{(3,74)} = 8.24$ , $p = 1 \times 10^{-4}$			$F_{(1,74)} = 0.46$ , $p = 0.50$	$F_{(1,74)} = 0.02$ , $p = 0.89$
					$t_{(74)} = -2.86$ , $p = 6 \times 10^{-3}$	$t_{(74)} = 0.29$ , $p = 0.77$	$t_{(74)} = 1.39$ , $p = 0.17$		
C5-M-DC	$F_{(1,109)} = 4.36$ , $p = 0.04$	$F_{(1,74)} = 0.99$ , $p = 0.32$	$F_{(1,109)} = 0.02$ , $p = 0.90$	$F_{(2,74)} = 1.18$ , $p = 0.31$	$F_{(3,74)} = 3.69$ , $p = 0.02$			$F_{(1,74)} = 1.46$ , $p = 0.23$	$F_{(1,74)} = 0.16$ , $p = 0.69$
					$t_{(74)} = 3.23$ , $p = 2 \times 10^{-3}$	$t_{(74)} = 3.04$ , $p = 3 \times 10^{-3}$	$t_{(74)} = 1.54$ , $p = 0.13$		
C5:1	$F_{(1,109)} = 0.75$ , $p = 0.39$	$F_{(1,74)} = 2.49$ , $p = 0.12$	$F_{(1,109)} = 0.18$ , $p = 0.67$	$F_{(2,74)} = 0.001$ , $p = 0.99$	$F_{(3,74)} = 8.11$ , $p = 1 \times 10^{-4}$			$F_{(1,74)} = 0.11$ , $p = 0.74$	$F_{(1,74)} = 0.18$ , $p = 0.67$
					$t_{(74)} = 4.06$ , $p = 1 \times 10^{-4}$	$t_{(74)} = 3.70$ , $p = 4 \times 10^{-4}$	$t_{(74)} = 4.46$ , $p < 1 \times 10^{-4}$		
C5:1-DC	$F_{(1,109)} = 7.65$ , $p = 7 \times 10^{-3}$	$F_{(1,74)} = 0.05$ , $p = 0.82$	$F_{(1,109)} = 0.25$ , $p = 0.62$	$F_{(2,74)} = 2.63$ , $p = 0.08$	$F_{(3,74)} = 5.19$ , $p = 3 \times 10^{-3}$			$F_{(1,74)} = 0.04$ , $p = 0.83$	$F_{(1,74)} = 0.36$ , $p = 0.55$
					$t_{(74)} = 3.53$ , $p = 7 \times 10^{-4}$	$t_{(74)} = 3.52$ , $p = 8 \times 10^{-4}$	$t_{(74)} = 3.14$ , $p = 2 \times 10^{-3}$		
Hexoses									
Hexoses	$F_{(1,109)} = 10690$ , $p < 1 \times 10^{-4}$	$F_{(1,73)} = 0.43$ , $p = 0.51$	$F_{(1,109)} = 5.81$ , $p = 0.02$	$F_{(2,73)} = 0.35$ , $p = 0.71$	$F_{(3,73)} = 4.44$ , $p = 6 \times 10^{-3}$			$F_{(1,73)} = 5.33$ , $p = 0.02$	$F_{(1,73)} = 2.58$ , $p = 0.11$
					$t_{(73)} = 0.60$ , $p = 0.55$	$t_{(73)} = 0.48$ , $p = 0.63$	$t_{(73)} = 3.40$ , $p = 1 \times 10^{-3}$		
Ratios of acylcarnitines									
(C16+C18)/C0	$F_{(1,103)} = 1737$ , $p < 1 \times 10^{-4}$	$F_{(1,73)} = 0.06$ , $p = 0.81$	$F_{(1,103)} = 3.93$ , $p = 0.05$	$F_{(2,73)} = 1.88$ , $p = 0.16$	$F_{(3,73)} = 4.64$ , $p = 5 \times 10^{-3}$			$F_{(1,73)} = 1.53$ , $p = 0.22$	$F_{(1,73)} = 1.17$ , $p = 0.28$
					$t_{(73)} = 3.43$ , $p = 1 \times 10^{-3}$	$t_{(73)} = 0.73$ , $p = 0.47$	$t_{(73)} = 1.85$ , $p = 0.07$		
(C16+C18:1)/C2	$F_{(1,89)} = 224.7$ , $p < 1 \times 10^{-4}$	$F_{(1,71)} = 5.96$ , $p = 0.02$	$F_{(1,89)} = 5.22$ , $p = 0.02$	$F_{(2,71)} = 3.33$ , $p = 0.04$	$F_{(3,71)} = 20.81$ , $p < 1 \times 10^{-4}$			$F_{(1,71)} = 0.71$ , $p = 0.40$	$F_{(1,71)} = 0.29$ , $p = 0.59$
					$t_{(71)} = 4.18$ , $p = 1 \times 10^{-4}$	$t_{(71)} = 0.72$ , $p = 0.47$	$t_{(71)} = -2.56$ , $p = 0.01$		
(C2+C3+C4+C5)/C0	$F_{(1,108)} = 50.42$ , $p < 1 \times 10^{-4}$	$F_{(1,68)} = 5.13$ , $p = 0.03$	$F_{(1,108)} = 6.64$ , $p = 0.01$	$F_{(2,68)} = 2.34$ , $p = 0.10$	$F_{(3,68)} = 10.36$ , $p < 1 \times 10^{-4}$			$F_{(1,68)} = 0.14$ , $p = 0.71$	$F_{(1,68)} = 0.72$ , $p = 0.40$
					$t_{(68)} = -2.81$ , $p = 6 \times 10^{-3}$	$t_{(68)} = -1.95$ , $p = 0.05$	$t_{(68)} = 3.00$ , $p = 4 \times 10^{-3}$		